Piramal Pharma shares dip on 4 USFDA observations for Kentucky plant

• Piramal Pharma shares reacted to four USFDA observations at its Kentucky facility.
• The USFDA conducted a Good Manufacturing Practices inspection of the Lexington, Kentucky unit from December 3-10, 2025.
• Four observations were issued on Form 483, relating to procedural enhancements.
• These observations are expected to be classified as Voluntary Action Indicated (VAI).
• Piramal Pharma is preparing a detailed response to submit to the USFDA.

Why It Matters: USFDA observations for Piramal Pharma may affect its drug production and stock.